Australian Clinical Labs Ltd
ASX:ACL

Watchlist Manager
Australian Clinical Labs Ltd Logo
Australian Clinical Labs Ltd
ASX:ACL
Watchlist
Price: 2.64 AUD 0.76% Market Closed
Market Cap: 522m AUD
Section:
Profitability Summary
Profitability Summary
Past Growth
Margins
Return on Capital
Free Cash Flow
See Also

Profitability Summary

Australian Clinical Labs Ltd's profitability score is 62/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

62/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

62/100
Profitability
Score
62/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less
0
Revenue
+0%
3Y
-16%
5Y
-
10Y
-
0
Operating Income
+0%
3Y
-74%
5Y
-
10Y
-
0
Net Income
+0%
3Y
-77%
5Y
-
10Y
-

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Australian Clinical Labs Ltd

Revenue
728.3m AUD
Cost of Revenue
-127m AUD
Gross Profit
601.2m AUD
Operating Expenses
-533.8m AUD
Operating Income
67.5m AUD
Other Expenses
-36.8m AUD
Net Income
30.7m AUD

Margins Comparison
Australian Clinical Labs Ltd Competitors

Country Company Market Cap Gross
Margin 		Operating
Margin 		Net
Margin
AU
Australian Clinical Labs Ltd
ASX:ACL
525.7m AUD
83%
9%
4%
US
Cigna Corp
NYSE:CI
84.8B USD
10%
4%
2%
US
Cigna Group
XMUN:CGN
73.8B EUR
10%
4%
2%
US
CVS Health Corp
NYSE:CVS
84B USD
14%
3%
1%
DE
Fresenius Medical Care AG
XMUN:FME
27.1B EUR
24%
7%
3%
DE
Fresenius SE & Co KGaA
XETRA:FRE
23.9B EUR
24%
9%
2%
US
Laboratory Corporation of America Holdings
NYSE:LH
21.9B USD
28%
9%
6%
US
Quest Diagnostics Inc
NYSE:DGX
20.1B USD
33%
14%
9%
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13.8B EUR
24%
7%
3%
US
Hims & Hers Health Inc
NYSE:HIMS
14.4B USD
77%
6%
9%
US
DaVita Inc
NYSE:DVA
10.6B USD
32%
15%
7%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Australian Clinical Labs Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
AU
Australian Clinical Labs Ltd
ASX:ACL
525.7m AUD
18%
5%
18%
9%
US
Cigna Corp
NYSE:CI
84.8B USD
12%
3%
10%
6%
US
Cigna Group
XMUN:CGN
73.8B EUR
12%
3%
10%
6%
US
CVS Health Corp
NYSE:CVS
84B USD
7%
2%
6%
4%
DE
Fresenius Medical Care AG
XMUN:FME
27.1B EUR
4%
2%
5%
3%
DE
Fresenius SE & Co KGaA
XETRA:FRE
23.9B EUR
2%
1%
5%
3%
US
Laboratory Corporation of America Holdings
NYSE:LH
21.9B USD
9%
4%
8%
6%
US
Quest Diagnostics Inc
NYSE:DGX
20.1B USD
13%
6%
11%
9%
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13.8B EUR
4%
2%
5%
3%
US
Hims & Hers Health Inc
NYSE:HIMS
14.4B USD
37%
25%
24%
48%
US
DaVita Inc
NYSE:DVA
10.6B USD
261%
5%
13%
10%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less

See Also

Summary
ACL intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACL stock valuation using valuation multiples.
Wall Street Estimates
ACL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.